Farxiga vs Lantus: Switching Between Dapagliflozin and Insulin Glargine

How These Two Drugs Work Differently

Farxiga and Lantus sit on opposite sides of the glucose-lowering spectrum. Understanding their mechanisms is the starting point for any safe switch.

Farxiga: Blocking Glucose at the Kidney

Dapagliflozin (Farxiga) inhibits the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney. This transporter normally reclaims about 90% of filtered glucose back into the bloodstream. By blocking it, Farxiga forces the body to excrete roughly 40 to 80 grams of glucose per day through urine. The mechanism is insulin-independent, meaning it works regardless of beta-cell function or insulin resistance severity.

Because the drug acts on the kidney rather than the pancreas, hypoglycemia risk during monotherapy is minimal. Farxiga also produces modest weight loss and blood pressure reduction, both linked to its osmotic diuresis and caloric wasting effects.

Lantus: Replacing Basal Insulin

Insulin glargine (Lantus) is a modified human insulin analog designed to dissolve slowly from its subcutaneous injection depot, providing a near-peakless insulin profile over approximately 24 hours. It suppresses hepatic glucose output overnight and between meals [1]. The drug directly addresses insulin deficiency, making it the standard choice when endogenous insulin production becomes insufficient.

Lantus has no ceiling on glucose-lowering potency. Higher doses produce greater A1C reductions. That same dose-response relationship, though, means hypoglycemia risk scales with dose, particularly during the first weeks of titration.

The Core Trade-Off

Farxiga offers cardiovascular and renal protection with weight loss and low hypoglycemia risk, but its A1C-lowering capacity plateaus. Lantus provides unlimited glucose-lowering power and is necessary when beta-cell reserve is depleted, but it carries weight gain and hypoglycemia as trade-offs. Neither drug replaces the other in every scenario.

Head-to-Head Clinical Evidence

No single randomized trial directly compared dapagliflozin against insulin glargine as a primary endpoint. The comparison relies on indirect evidence from separate landmark trials and network meta-analyses.

DAPA-HF: The Cardiovascular Case for Farxiga

The DAPA-HF trial (N=4,744) enrolled patients with heart failure and reduced ejection fraction (HFrEF), with or without diabetes. Dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) [2]. The benefit appeared within 28 days and was consistent regardless of diabetes status.

This trial did not compare Farxiga against insulin. But it established that dapagliflozin offers organ-protective effects beyond glucose control, a factor that weighs heavily in switching decisions.

ORIGIN: Lantus and Cardiovascular Neutrality

The ORIGIN trial (N=12,537) randomized patients with early type 2 diabetes or pre-diabetes to insulin glargine versus standard care, following them for a median of 6.2 years. Cardiovascular outcomes were neutral: the incidence of major adverse cardiovascular events (MACE) was similar between groups (hazard ratio 1.02, 95% CI 0.94 to 1.11) [3]. Insulin glargine did not increase or decrease CV risk, but it caused more hypoglycemia (1.00 vs 0.31 severe episodes per 100 person-years) and a mean weight gain of 1.6 kg.

What Indirect Comparisons Show

A 2020 network meta-analysis published in Diabetes, Obesity and Metabolism pooled data from SGLT2 inhibitor and basal insulin trials in type 2 diabetes. SGLT2 inhibitors as a class produced roughly 1 to 3 kg less weight gain than basal insulin analogs with similar A1C reductions in patients with baseline A1C between 7.5% and 9.0%. The American Diabetes Association (ADA) 2024 Standards of Care now position SGLT2 inhibitors ahead of basal insulin in the treatment algorithm for most patients with type 2 diabetes, particularly those with established cardiovascular or kidney disease [4].

When Switching from Farxiga to Lantus Makes Sense

Not every patient can remain on an SGLT2 inhibitor indefinitely. Several clinical scenarios call for a transition to basal insulin.

Progressive Beta-Cell Decline

Type 2 diabetes is a progressive disease. When A1C rises above 9% to 10% despite maximum oral therapy including Farxiga, endogenous insulin production has likely declined to the point where exogenous insulin is necessary. The ADA recommends considering insulin when patients show symptoms of catabolism (unexplained weight loss, polyuria, polydipsia) regardless of current A1C.

eGFR Below 25 mL/min/1.73 m²

Farxiga's glucose-lowering efficacy depends on glomerular filtration. As kidney function declines below an eGFR of 25, the glycemic benefit diminishes substantially, although cardiorenal protective effects may persist. The FDA label for dapagliflozin permits continued use for heart failure and CKD indications at lower eGFR values, but for glucose control specifically, switching to insulin becomes practical when filtration rate is severely reduced [5].

Recurrent Genitourinary Infections

SGLT2 inhibitors increase urinary glucose, creating a favorable environment for yeast and bacteria. Patients who develop recurrent genital mycotic infections or urinary tract infections despite preventive measures may need to discontinue Farxiga and transition to an alternative glucose-lowering strategy. Lantus carries no such infection risk.

How to Execute the Farxiga-to-Lantus Switch

Stop Farxiga on the morning of the switch. Dapagliflozin has a half-life of approximately 12.9 hours, so glucosuric effects persist for roughly 2 to 3 days. Start insulin glargine at a conservative dose of 0.1 to 0.2 units/kg (typically 10 units for most adults) on the same evening or the following morning. Titrate by 2 units every 3 days targeting a fasting glucose of 80 to 130 mg/dL per ADA recommendations. During the overlap window while Farxiga's effect wanes, hypoglycemia risk is elevated, so initial insulin doses should err on the lower side.

Monitor fasting blood glucose daily for at least 2 weeks. Expect glucose to rise slightly in the first 48 to 72 hours as the SGLT2 inhibitor clears, then stabilize as insulin titration catches up.

When Switching from Lantus to Farxiga Makes Sense

The reverse switch, moving from basal insulin to an SGLT2 inhibitor, is increasingly common as guidelines favor cardiorenal-protective agents earlier in treatment.

Patients with Established ASCVD or Heart Failure

The 2024 ADA Standards of Care recommend SGLT2 inhibitors for patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease, independent of A1C [4]. If a patient on Lantus has one of these conditions and still has adequate beta-cell reserve (suggested by a C-peptide level above 1.0 ng/mL on fasting), switching to or adding dapagliflozin provides organ protection that insulin alone does not.

Patients Gaining Weight on Insulin

Weight gain during insulin therapy is common. The ORIGIN trial documented a mean gain of 1.6 kg over 6.2 years with glargine [3]. In clinical practice, weight gain can be substantially higher, particularly at doses above 0.5 units/kg/day. Replacing basal insulin with Farxiga can reverse this trajectory, producing 2 to 3 kg of weight loss in the first 6 to 12 months according to pooled SGLT2 inhibitor data.

Low Insulin Doses Suggesting Residual Beta-Cell Function

Patients on Lantus at doses below 0.3 units/kg/day with A1C at or near goal may have enough endogenous insulin production to maintain glycemic control without exogenous insulin. These patients are candidates for a supervised switch to oral therapy.

How to Execute the Lantus-to-Farxiga Switch

This transition requires more caution than the reverse. Start dapagliflozin 10 mg daily while simultaneously reducing insulin glargine by 20% to 30%. If the pre-switch Lantus dose is below 20 units, consider reducing by 50% or stopping entirely if C-peptide confirms adequate endogenous production.

Monitor fasting glucose and at least one pre-meal glucose daily for 2 to 4 weeks. If fasting glucose remains below 180 mg/dL without hypoglycemia, continue reducing insulin by 10% to 20% weekly until discontinued. If glucose rises above 250 mg/dL on two consecutive days, reinstate the prior insulin dose and reassess.

"Abruptly stopping basal insulin without confirming residual beta-cell function risks diabetic ketoacidosis, even in type 2 diabetes," as noted in the ADA's 2024 pharmacologic treatment chapter. This risk, while rare in type 2 diabetes, is real in patients with long disease duration or low C-peptide.

Using Both Drugs Together

Switching is not the only option. Many patients benefit from combination therapy.

The Rationale for Co-Prescribing

Adding dapagliflozin to existing basal insulin therapy reduces A1C by an additional 0.4 to 0.6 percentage points while partially offsetting insulin-associated weight gain. A 24-week randomized trial of dapagliflozin added to insulin therapy showed a placebo-subtracted A1C reduction of 0.57% with 1.67 kg less weight gain compared to placebo plus insulin [6].

Practical Dosing When Combining

When adding Farxiga to a stable Lantus regimen, reduce insulin by 10% to 20% on day one to account for the additive glucose-lowering effect. This preemptive reduction lowers hypoglycemia risk during the first week while dapagliflozin reaches steady state. Patients on insulin doses above 0.5 units/kg may not need an insulin reduction if their A1C remains above 8%.

Monitoring the Combination

Check fasting glucose daily for 2 weeks after adding the SGLT2 inhibitor. Watch for signs of volume depletion (dizziness on standing, reduced urine output, elevated creatinine), especially in patients over 65 or those taking diuretics. Renal function should be checked at 1 month and then every 3 to 6 months per KDIGO 2024 guidelines.

Safety Comparison: Side-by-Side

The safety profiles of these two drugs differ in almost every dimension.

Hypoglycemia

Farxiga monotherapy carries a hypoglycemia incidence similar to placebo (roughly 2% to 4%). Lantus causes clinically significant hypoglycemia in approximately 10% to 15% of patients annually at typical doses. The risk increases with renal impairment, missed meals, and concurrent sulfonylurea use. When combining both drugs, the risk sits between these two extremes, driven primarily by the insulin dose.

Euglycemic DKA

Dapagliflozin carries a rare but serious risk of euglycemic diabetic ketoacidosis (DKA), where ketoacidosis develops with blood glucose below 250 mg/dL. The FDA issued a safety communication in 2015 and updated labeling in 2020. Risk factors include surgery, prolonged fasting, acute illness, and significant insulin dose reduction. Patients switching from Lantus to Farxiga are particularly vulnerable if insulin is withdrawn too quickly. Lantus carries no DKA risk when dosed appropriately.

Genital and Urinary Infections

Farxiga increases the risk of genital mycotic infections (vulvovaginal candidiasis in women, balanitis in men) by approximately threefold compared to placebo. UTI risk is modestly elevated. Lantus does not affect infection rates. This difference matters most in patients with a history of recurrent infections.

Weight and Body Composition

Farxiga produces a consistent 2 to 3 kg weight reduction, primarily from glycosuria-induced caloric loss and mild osmotic diuresis. About one-third of the weight lost is fat mass. Lantus promotes weight gain through anabolic insulin effects and defensive eating to prevent hypoglycemia. The net weight difference between the two drugs can reach 3 to 5 kg over 12 months.

Cost and Access Considerations

Farxiga (brand) costs approximately $550 to $600 per month without insurance in 2026. No generic dapagliflozin is available in the United States as of this writing. Lantus has biosimilar alternatives (Semglee, Rezvoglar) priced at roughly $150 to $300 per month, and the authorized generic of Lantus is available at lower cost.

For patients with commercial insurance, both drugs typically require prior authorization. Medicare Part D covers Lantus and biosimilars on most formularies. Farxiga coverage under Part D varies by plan but has expanded following its heart failure and CKD indications. The Inflation Reduction Act's $35 monthly insulin cap applies to Lantus and its biosimilars for Medicare beneficiaries but does not cover Farxiga.

Patients without insurance or with high copays should explore manufacturer patient assistance programs: AstraZeneca offers the Farxiga Savings Program, and Sanofi offers the Lantus Savings Card, both reducing out-of-pocket costs to as low as $0 to $25 per month for eligible commercially insured patients.

Choosing the Right Drug at the Right Time

The decision between Farxiga and Lantus depends on disease stage, comorbidities, and patient priorities.

Start with Farxiga When

The patient has type 2 diabetes with established heart failure (HFrEF or HFpEF), CKD with eGFR above 25, or high ASCVD risk. The A1C is below 9%, and the patient has adequate beta-cell function. Weight management is a priority. The patient prefers oral medication over injections.

Start with Lantus When

The A1C exceeds 9% to 10% with catabolic symptoms. The patient has advanced kidney disease where SGLT2 glycemic efficacy is minimal. C-peptide testing confirms low endogenous insulin production. The patient has recurrent genitourinary infections.

Consider Combining When

A1C remains above goal on one agent alone, the patient has cardiovascular or renal indications for an SGLT2 inhibitor, and glycemic control requires basal insulin supplementation. The 2024 ADA Standards of Care explicitly support this combination [4].

The choice is not permanent. Type 2 diabetes changes over time, and the treatment plan should change with it. A patient who starts on Farxiga at diagnosis may eventually need Lantus as beta-cell function declines. A patient stabilized on Lantus may benefit from adding or switching to Farxiga if heart failure or CKD develops. Regular reassessment every 3 to 6 months keeps the regimen matched to the patient's current physiology.